Palmitic Acid-Conjugated Radiopharmaceutical for Integrin α(v)β(3)-Targeted Radionuclide Therapy

Peptide receptor radionuclide therapy (PRRT) is an emerging approach for patients with unresectable or metastatic tumors. Our previously optimized RGD peptide (3PRGD(2)) has excellent targeting specificity for a variety of integrin α(v)β(3)/α(v)β(5)-positive tumors and has been labeled with the ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guangjie, Gao, Hannan, Luo, Chuangwei, Zhao, Xiaoyu, Luo, Qi, Shi, Jiyun, Wang, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321335/
https://www.ncbi.nlm.nih.gov/pubmed/35890224
http://dx.doi.org/10.3390/pharmaceutics14071327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321335/
https://www.ncbi.nlm.nih.gov/pubmed/35890224
http://dx.doi.org/10.3390/pharmaceutics14071327

Ejemplares similares